+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biomarkers Market - Global Forecast to 2030- Product Image
Biomarkers Market - Global Forecast to 2030- Product Image
New

Biomarkers Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082615
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biomarkers Market grew from USD 59.69 billion in 2024 to USD 68.30 billion in 2025. It is expected to continue growing at a CAGR of 14.30%, reaching USD 133.17 billion by 2030.

Biomarkers are revolutionizing the way we detect, treat, and monitor disease, driving a paradigm shift across diagnostics, drug development, and personalized care. As molecular and clinical insights converge, the demand for precise, predictive, and actionable biological indicators continues to accelerate. This executive summary provides a comprehensive overview of the current biomarker landscape, highlighting key innovations, market drivers, and emerging challenges. By unpacking transformative shifts, regulatory influences, segmentation trends, regional dynamics, and competitive positioning, this summary equips decision-makers with the knowledge required to navigate an increasingly complex and opportunity-rich environment. The subsequent sections offer a roadmap for aligning strategies, optimizing investments, and capitalizing on high-impact areas within the biomarker ecosystem.

Transformative Shifts in the Landscape

Over the past decade, the biomarker landscape has undergone rapid transformation fueled by advances in high-throughput sequencing, mass spectrometry, and imaging modalities. The integration of artificial intelligence and machine learning into analytical pipelines has streamlined assay development, enabling the discovery of novel genomic biomarkers at unprecedented speed. Digital biomarkers derived from wearable imaging technologies now complement traditional proteomic markers, offering continuous monitoring of physiological parameters via MRI and PET scans. Simultaneously, the shift from one-size-fits-all diagnostics to tailored companion diagnostics underscores the move toward personalized medicine. This evolution is further propelled by regulatory encouragement of precision approaches, fostering closer collaboration among clinical laboratories, pharmaceutical companies, and research organizations to drive translational breakthroughs.

Cumulative Impact of United States Tariffs 2025

In 2025, newly enacted United States tariffs on imported reagents, instrumentation, and assay kits have exerted significant pressure on cost structures and supply chains. Margins for genomic biomarker providers have tightened as DNA-based and RNA-based assay components imported from key manufacturing hubs face elevated duties. Pharmaceutical companies engaged in lead optimization and target identification report extended procurement timelines, prompting a pivot toward domestic production partnerships. Clinical laboratories, particularly independent labs reliant on specialized mass spectrometry consumables, have initiated strategic stockpiling and local vendor development to mitigate disruption. Concurrently, regulatory approval pathways are adapting, with agencies offering streamlined analytical validation guidance to offset tariff-induced delays. These cumulative policy shifts are reshaping sourcing strategies and accelerating investment in regional manufacturing capabilities.

Key Segmentation Insights

A detailed segmentation analysis reveals where growth and innovation converge. When examining applications, disease diagnostics spans cardiovascular diseases-where biomarkers for heart failure and myocardial infarction are vital-infectious diseases that bifurcate into bacterial and viral infection markers, and oncology, which drives demand for breast and lung cancer biomarkers. In drug discovery, lead optimization and target identification workflows increasingly rely on metabolomic biomarkers and protein expression profiling. Personalized medicine hinges on companion diagnostics and the therapeutic segment, leveraging DNA-based and RNA-based genomic biomarkers alongside clinical sensitivity and specificity studies. From a type perspective, genomic, proteomic, and metabolomic biomarkers each play distinct roles: genomic markers enable predictive risk assessment, proteomic biomarkers derived from assay development and reference standards inform real-time protein expression, and metabolomic signatures guide therapeutic response monitoring. Therapeutic area segmentation highlights cardiology, neurology-with a focus on Alzheimer’s disease and Parkinson’s disease-and oncology needs, each demanding tailored validation strategies, whether through analytical validation protocols or regulatory approval pathways. End-user segmentation underscores divergent requirements among hospital-based labs, independent clinical laboratories, biopharmaceutical and generic pharmaceutical companies, as well as research organizations pursuing next-generation sequencing innovations. Finally, technology segmentation illustrates how emerging platforms such as mass spectrometry, next-generation sequencing, and imaging modalities like PET scans are redefining assay sensitivity and throughput.

Key Regional Insights

Regional dynamics shape strategic priorities and investment allocations. In the Americas, the prevalence of robust biomanufacturing infrastructure and supportive regulatory frameworks accelerates adoption of next-generation sequencing and proteomic assays, while North American research hubs expand mass spectrometry capabilities. In Europe, Middle East & Africa, harmonization efforts under international regulatory coalitions catalyze cross-border clinical validation studies, particularly for oncology biomarkers. Meanwhile, Asia-Pacific markets, driven by rapid healthcare digitization and large patient populations, are scaling molecular diagnostics and digital imaging solutions, with governments incentivizing local assay development to reduce dependency on imports. Collaboration between multinational diagnostic firms and regional test providers is reinforcing supply chain resilience and diversifying validation studies across emerging therapeutic areas.

Key Companies Insights

Competitive dynamics are defined by a diverse roster of industry leaders and innovators. Abbott Laboratories and Thermo Fisher Scientific, Inc. continue to dominate reagent and instrument markets, while QIAGEN GmbH and PerkinElmer, Inc. lead in genomic and proteomic assay kits. F. Hoffmann-La Roche, Ltd. and Merck KGaA intensify partnerships with research organizations to drive target identification in neurology and cardiology. Bio-Rad Laboratories, Inc., Biocrates Life Sciences AG, and BioAgilytix bring advanced mass spectrometry and assay development expertise, whereas Biofourmis Inc., Nightingale Health Plc, and BioStarks pioneer digital biomarker analytics. Smaller specialists such as APIS Assay Technologies Limited and Owlstone Medical Limited deliver niche assay solutions, complementing larger portfolios. Meanwhile, Charles River Laboratories, Inc. and Owkin Inc. bridge translational gaps, supporting analytical and clinical validation studies. This varied ecosystem of biopharmaceutical companies, generic pharmaceutical companies, clinical laboratories, and research organizations fosters both competition and collaborative innovation.

Actionable Recommendations for Industry Leaders

Prioritize strategic alliances to streamline end-to-end biomarker workflows and leverage complementary capabilities; invest in integrated platforms combining next-generation sequencing, mass spectrometry, and imaging modalities to enhance assay sensitivity; accelerate the development of regulatory validation strategies by engaging with approval pathway experts early in the analytical and clinical validation processes; diversify sourcing by establishing regional manufacturing partnerships to mitigate geopolitical risks and tariff impacts; allocate resources to digital biomarker initiatives, harnessing wearable imaging technologies and AI-driven analytics for real-time patient monitoring; and cultivate cross-disciplinary teams that bridge clinical, analytical, and data sciences to foster rapid translation from discovery to diagnostic application.

Conclusion

The biomarker sector stands at the crossroads of innovation and regulation, driven by advanced technologies and evolving policy landscapes. Segmentation, regional insights, and competitive positioning underscore the importance of flexible strategies that adapt to tariff fluctuations, validation requirements, and market-specific needs. By capitalizing on collaborative networks, integrating multi-omic platforms, and aligning with regulatory guidelines, organizations can deliver high-impact biomarkers that address critical disease areas. The interplay of emerging analytical techniques, personalized medicine imperatives, and digital biomarker advances presents an unparalleled opportunity to reshape healthcare delivery and improve patient outcomes.

Market Segmentation & Coverage

This research report categorizes the Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Disease Diagnostics
    • Cardiovascular Diseases
    • Infectious Diseases
      • Bacterial Infections
      • Viral Infections
    • Oncology
  • Drug Discovery
    • Lead Optimization
    • Target Identification
  • Personalized Medicine
    • Companion Diagnostics
    • Therapeutic Segment
  • Genomic Biomarkers
    • DNA-based Biomarkers
    • RNA-based Biomarkers
  • Metabolomic Biomarkers
  • Proteomic Biomarkers
    • Protein Expression
  • Cardiology
    • Heart Failure
    • Myocardial Infarction
  • Neurology
    • Alzheimer's Disease
    • Parkinson's Disease
  • Oncology
    • Breast Cancer Biomarkers
    • Lung Cancer Biomarkers
  • Clinical Laboratories
    • Hospital-Based Labs
    • Independent Labs
  • Pharmaceutical Companies
    • Biopharmaceutical Companies
    • Generic Pharmaceutical Companies
  • Research Organizations
  • Analytical Validation
    • Assay Development
    • Reference Standard
  • Clinical Validation
    • Sensitivity and Specificity Studies
  • Regulatory Validation
    • Regulatory Approval Pathways
  • Imaging Technologies
    • MRI
    • PET Scans
  • Mass Spectrometry
  • Next-generation Sequencing

This research report categorizes the Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biomarkers Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Abcam PLC
  • APIS Assay Technologies Limited
  • Augurex Life Sciences Corp
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix
  • Biocrates Life Sciences AG
  • Biofourmis Inc.
  • Biognosys AG
  • BioStarks
  • Charles River Laboratories, Inc.
  • Elo Health, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Merck KgaA
  • Nightingale Health Plc
  • Owkin Inc.
  • Owlstone Medical Limited
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • Proteomedix AG
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Thermo Fisher Scientific, Inc.
  • VivoSense, Inc

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biomarkers Market, by Application
8.1. Introduction
8.2. Disease Diagnostics
8.2.1. Cardiovascular Diseases
8.2.2. Infectious Diseases
8.2.2.1. Bacterial Infections
8.2.2.2. Viral Infections
8.2.3. Oncology
8.3. Drug Discovery
8.3.1. Lead Optimization
8.3.2. Target Identification
8.4. Personalized Medicine
8.4.1. Companion Diagnostics
8.4.2. Therapeutic Segment
9. Biomarkers Market, by Type
9.1. Introduction
9.2. Genomic Biomarkers
9.2.1. DNA-based Biomarkers
9.2.2. RNA-based Biomarkers
9.3. Metabolomic Biomarkers
9.4. Proteomic Biomarkers
9.4.1. Protein Expression
10. Biomarkers Market, by Therapeutic Area
10.1. Introduction
10.2. Cardiology
10.2.1. Heart Failure
10.2.2. Myocardial Infarction
10.3. Neurology
10.3.1. Alzheimer's Disease
10.3.2. Parkinson's Disease
10.4. Oncology
10.4.1. Breast Cancer Biomarkers
10.4.2. Lung Cancer Biomarkers
11. Biomarkers Market, by End Users
11.1. Introduction
11.2. Clinical Laboratories
11.2.1. Hospital-Based Labs
11.2.2. Independent Labs
11.3. Pharmaceutical Companies
11.3.1. Biopharmaceutical Companies
11.3.2. Generic Pharmaceutical Companies
11.4. Research Organizations
12. Biomarkers Market, by Biomarker Validation
12.1. Introduction
12.2. Analytical Validation
12.2.1. Assay Development
12.2.2. Reference Standard
12.3. Clinical Validation
12.3.1. Sensitivity and Specificity Studies
12.4. Regulatory Validation
12.4.1. Regulatory Approval Pathways
13. Biomarkers Market, by Technologies
13.1. Introduction
13.2. Imaging Technologies
13.2.1. MRI
13.2.2. PET Scans
13.3. Mass Spectrometry
13.4. Next-generation Sequencing
14. Americas Biomarkers Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Biomarkers Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Biomarkers Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. Abcam PLC
17.3.3. APIS Assay Technologies Limited
17.3.4. Augurex Life Sciences Corp
17.3.5. Bio-Rad Laboratories, Inc.
17.3.6. BioAgilytix
17.3.7. Biocrates Life Sciences AG
17.3.8. Biofourmis Inc.
17.3.9. Biognosys AG
17.3.10. BioStarks
17.3.11. Charles River Laboratories, Inc.
17.3.12. Elo Health, Inc.
17.3.13. F. Hoffmann-La Roche, Ltd.
17.3.14. Merck KgaA
17.3.15. Nightingale Health Plc
17.3.16. Owkin Inc.
17.3.17. Owlstone Medical Limited
17.3.18. PerkinElmer, Inc.
17.3.19. Personalis, Inc.
17.3.20. Proteomedix AG
17.3.21. QIAGEN GmbH
17.3.22. Siemens Healthineers AG
17.3.23. Sino Biological Inc.
17.3.24. Thermo Fisher Scientific, Inc.
17.3.25. VivoSense, Inc
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BIOMARKERS MARKET MULTI-CURRENCY
FIGURE 2. BIOMARKERS MARKET MULTI-LANGUAGE
FIGURE 3. BIOMARKERS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOMARKERS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOMARKERS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOMARKERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOMARKERS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOMARKERS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOMARKERS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOMARKERS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOMARKERS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC SEGMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOMARKERS MARKET SIZE, BY DNA-BASED BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOMARKERS MARKET SIZE, BY RNA-BASED BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOMARKERS MARKET SIZE, BY PROTEIN EXPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOMARKERS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOMARKERS MARKET SIZE, BY BREAST CANCER BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOMARKERS MARKET SIZE, BY LUNG CANCER BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOMARKERS MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOMARKERS MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOMARKERS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOMARKERS MARKET SIZE, BY GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOMARKERS MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOMARKERS MARKET SIZE, BY REFERENCE STANDARD, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOMARKERS MARKET SIZE, BY SENSITIVITY AND SPECIFICITY STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOMARKERS MARKET SIZE, BY REGULATORY APPROVAL PATHWAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOMARKERS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOMARKERS MARKET SIZE, BY PET SCANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 137. CANADA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. CANADA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 139. CANADA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 140. CANADA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 141. CANADA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 142. CANADA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. CANADA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 144. CANADA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 145. CANADA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 146. CANADA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 147. CANADA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 148. CANADA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 149. CANADA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 150. CANADA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 151. CANADA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 152. CANADA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 153. CANADA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 154. CANADA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 155. CANADA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 156. CANADA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 157. CANADA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 169. MEXICO BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 170. MEXICO BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 172. MEXICO BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 173. MEXICO BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 174. MEXICO BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 175. MEXICO BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 176. MEXICO BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 177. MEXICO BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 178. MEXICO BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 244. CHINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. CHINA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 246. CHINA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 247. CHINA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 248. CHINA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 249. CHINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 250. CHINA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 251. CHINA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 252. CHINA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 253. CHINA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 254. CHINA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 255. CHINA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 256. CHINA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 257. CHINA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 258. CHINA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 259. CHINA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 260. CHINA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 261. CHINA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 262. CHINA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 263. CHINA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 264. CHINA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 265. INDIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. INDIA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 267. INDIA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 268. INDIA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 269. INDIA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 270. INDIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 271. INDIA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 272. INDIA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 273. INDIA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 274. INDIA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 275. INDIA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 276. INDIA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 277. INDIA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 278. INDIA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 279. INDIA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 280. INDIA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 281. INDIA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 282. INDIA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 283. INDIA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 284. INDIA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 285. INDIA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 289. INDONESIA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 290. INDONESIA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 291. INDONESIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 292. INDONESIA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 293. INDONESIA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 294. INDONESIA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 295. INDONESIA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 296. INDONESIA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 297. INDONESIA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 298. INDONESIA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 299. INDONESIA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 300. INDONESIA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 301. INDONESIA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 302. INDONESIA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 303. INDONESIA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 304. INDONESIA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 305. INDONESIA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 306. INDONESIA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 307. JAPAN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 308. JAPAN BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 309. JAPAN BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 310. JAPAN BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 311. JAPAN BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 312. JAPAN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 313. JAPAN BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 314. JAPAN BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 315. JAPAN BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 316. JAPAN BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 317. JAPAN BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 318. JAPAN BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 319. JAPAN BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 320. JAPAN BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 321. JAPAN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 322. JAPAN BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 323. JAPAN BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 324. JAPAN BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 325. JAPAN BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 326. JAPAN BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 327. JAPAN BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 328. MALAYSIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 329. MALAYSIA BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 330. MALAYSIA BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 331. MALAYSIA BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 332. MALAYSIA BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 333. MALAYSIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 345. MALAYSIA BIOMARKERS MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 346. MALAYSIA BIOMARKERS MARKET SIZE, BY REGULATORY VALIDATION, 2018-2030 (USD MILLION)
TABLE 347. MALAYSIA BIOMARKERS MARKET SIZE, BY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 348. MALAYSIA BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 349. PHILIPPINES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 350. PHILIPPINES BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 351. PHILIPPINES BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 352. PHILIPPINES BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 353. PHILIPPINES BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
TABLE 354. PHILIPPINES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 355. PHILIPPINES BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 356. PHILIPPINES BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 357. PHILIPPINES BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 358. PHILIPPINES BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 359. PHILIPPINES BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 360. PHILIPPINES BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 361. PHILIPPINES BIOMARKERS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 362. PHILIPPINES BIOMARKERS MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 363. PHILIPPINES BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 364. PHILIPPINES BIOMARKERS MARKET SIZE, BY BIOMARKER VALIDATION, 2018-2030 (USD MILLION)
TABLE 365. PHILIPPINES BIOMARKERS MARKET SIZE, BY ANALYTICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 366. PHILIPPINES BIOMARK

Companies Mentioned

  • Abbott Laboratories
  • Abcam PLC
  • APIS Assay Technologies Limited
  • Augurex Life Sciences Corp
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix
  • Biocrates Life Sciences AG
  • Biofourmis Inc.
  • Biognosys AG
  • BioStarks
  • Charles River Laboratories, Inc.
  • Elo Health, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Merck KgaA
  • Nightingale Health Plc
  • Owkin Inc.
  • Owlstone Medical Limited
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • Proteomedix AG
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Thermo Fisher Scientific, Inc.
  • VivoSense, Inc

Methodology

Loading
LOADING...

Related Topics

Related Reports

Brain Biomarkers Market - Global Forecast to 2030 - Product Image

Brain Biomarkers Market - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Biomarker Discovery Outsourcing Services Market Size, Share & Trends Analysis Report by Biomarker Type (Predictive, Safety), Therapeutic Area (Oncology, Neurology), Phase, End Use, and Region with Growth Forecasts, 2025-2030 - Product Image

Biomarker Discovery Outsourcing Services Market Size, Share & Trends Analysis Report by Biomarker Type (Predictive, Safety), Therapeutic Area (Oncology, Neurology), Phase, End Use, and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Personalized Medicine Biomarkers Market Size, Share & Trends Analysis Report By Application (Early Detection, Treatment Selection, Monitoring), By Indication (Oncology, Neurology), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Personalized Medicine Biomarkers Market Size, Share & Trends Analysis Report By Application (Early Detection, Treatment Selection, Monitoring), By Indication (Oncology, Neurology), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Cancer Biomarkers Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Biomarker Type; Technology; Application; and End-User - Product Image

Cancer Biomarkers Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Biomarker Type; Technology; Application; and End-User

  • Report
  • 62 Pages
  • Global
From

About the Biomarkers Market

Metabolomics biomarkers are a type of biomarker used to measure and analyze the metabolites present in a biological sample. Metabolites are small molecules that are produced as a result of metabolic processes, and they can provide valuable information about the health of an individual. Metabolomics biomarkers are used to identify and quantify metabolites in order to gain insight into the metabolic pathways of an organism. This information can be used to diagnose diseases, monitor the progression of a disease, and evaluate the effectiveness of treatments. Metabolomics biomarkers are used in a variety of fields, including drug discovery, toxicology, nutrition, and personalized medicine. They are also used to identify biomarkers for diseases such as cancer, diabetes, and cardiovascular disease. Companies in the metabolomics biomarker market include Metabolon, Biocrates Life Sciences, Metabolomic Technologies, Metabolon, and Metabolomics Technologies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.